{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:56:20Z","timestamp":1787003780194,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T00:00:00Z","timestamp":1140566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1038\/sj.npp.1301047","type":"journal-article","created":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T11:23:26Z","timestamp":1140607406000},"page":"514-521","source":"Crossref","is-referenced-by-count":117,"title":["Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors"],"prefix":"10.1038","volume":"32","author":[{"given":"Kenji","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Iyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,2,22]]},"reference":[{"key":"BF1301047_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1254\/jphs.CRJ04005X","volume":"97","author":"JE Bermack","year":"2005","unstructured":"Bermack JE, Debonnel G (2005). The role of sigma receptors in depression. J Pharmacol Sci 97: 317\u2013336.","journal-title":"J Pharmacol Sci"},{"key":"BF1301047_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/10673229609017192","volume":"3","author":"JT Coyle","year":"1996","unstructured":"Coyle JT (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3: 241\u2013253.","journal-title":"Harv Rev Psychiatry"},{"key":"BF1301047_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","volume":"174","author":"JT Coyle","year":"2004","unstructured":"Coyle JT, Tsai G (2004). The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berlin) 174: 32\u201338.","journal-title":"Psychopharmacology (Berlin)"},{"key":"BF1301047_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/0024-3205(95)02248-1","volume":"58","author":"G Debonnel","year":"1996","unstructured":"Debonnel G, de Montigny C (1996). Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 58: 721\u2013734.","journal-title":"Life Sci"},{"key":"BF1301047_CR5","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMra035458","volume":"349","author":"R Freedman","year":"2003","unstructured":"Freedman R (2003). Schizophrenia. N Engl J Med 349: 1738\u20131749.","journal-title":"N Engl J Med"},{"key":"BF1301047_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.brainres.2004.04.072","volume":"1016","author":"G Fukami","year":"2004","unstructured":"Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M (2004). Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res 1016: 90\u201395.","journal-title":"Brain Res"},{"key":"BF1301047_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","volume":"56","author":"MF Green","year":"2004","unstructured":"Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S et al (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56: 301\u2013307.","journal-title":"Biol Psychiatry"},{"key":"BF1301047_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","volume":"519","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Fujita Y, Shimizu E, Iyo M (2005a). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 519: 114\u2013117.","journal-title":"Eur J Pharmacol"},{"key":"BF1301047_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","volume":"60","author":"K Hashimoto","year":"2003","unstructured":"Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N et al (2003). Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60: 572\u2013576.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1301047_CR10","unstructured":"Hashimoto K, Ishiwata K (2006). Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des (in press)."},{"key":"BF1301047_CR11","first-page":"147","volume":"4","author":"K Hashimoto","year":"2004","unstructured":"Hashimoto K, Okamura N, Shimizu E, Iyo M (2004). Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr Med Chem CNS Agents 4: 147\u2013154.","journal-title":"Curr Med Chem CNS Agents"},{"key":"BF1301047_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2174\/1573400054065569","volume":"1","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Shimizu E, Iyo M (2005b). Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev 1: 151\u2013163.","journal-title":"Curr Psychiatry Rev"},{"key":"BF1301047_CR13","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/j.1460-9568.1997.tb00756.x","volume":"9","author":"K Hashimoto","year":"1997","unstructured":"Hashimoto K, Tomitaka S, Bi Y, Narita N, Minabe Y, Iyo M (1997). Rolipram, a selective phosphodiesterase type-IV inhibitor, prevents induction of heat shock protein HSP-70 and hsp-70 mRNA in rat retrosplenial cortex by the NMDA receptor antagonist dizocilpine. Eur J Neurosci 9: 1891\u20131901.","journal-title":"Eur J Neurosci"},{"key":"BF1301047_CR14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3565(24)39299-7","volume":"293","author":"T Hayashi","year":"2000","unstructured":"Hayashi T, Maurice T, Su TP (2000). Ca2+ signaling via sigma-1 receptors: novel regulatory mechanism affecting intracellular Ca2+ concentration. J Pharmacol Exp Ther 293: 788\u2013798.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1301047_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1073\/pnas.98.2.491","volume":"98","author":"T Hayashi","year":"2001","unstructured":"Hayashi T, Su TP (2001). Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci USA 98: 491\u2013496.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1301047_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/00023210-200418050-00001","volume":"18","author":"T Hayashi","year":"2004","unstructured":"Hayashi T, Su TP (2004). Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18: 269\u2013284.","journal-title":"CNS Drugs"},{"key":"BF1301047_CR17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/sj.mp.4001551","volume":"9","author":"DC Javitt","year":"2004","unstructured":"Javitt DC (2004). Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9: 984\u2013987.","journal-title":"Mol Psychiatry"},{"key":"BF1301047_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.npp.1300313","volume":"29","author":"DC Javitt","year":"2004","unstructured":"Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H (2004). Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor\/glycine-site agonists. Neuropsychopharmacology 29: 300\u2013307.","journal-title":"Neuropsychopharmacology"},{"key":"BF1301047_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301\u20131308.","journal-title":"Am J Psychiatry"},{"key":"BF1301047_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201\u2013225.","journal-title":"Neuropsychopharmacology"},{"key":"BF1301047_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/hrp.7.3.125","volume":"7","author":"JH Krystal","year":"1999","unstructured":"Krystal JH, D\u2019Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS et al (1999). NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 7: 125\u2013143.","journal-title":"Harv Rev Psychiatry"},{"key":"BF1301047_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.schres.2004.07.005","volume":"74","author":"MM Kurtz","year":"2005","unstructured":"Kurtz MM (2005). Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res 74: 15\u201326.","journal-title":"Schizophr Res"},{"key":"BF1301047_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/00008877-200311000-00006","volume":"14","author":"S Mandillo","year":"2003","unstructured":"Mandillo S, Rinaldi A, Oliverio A, Mele A (2003). Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 14: 533\u2013544.","journal-title":"Behav Pharmacol"},{"key":"BF1301047_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1527-3458.1998.tb00038.x","volume":"4","author":"K Matsuno","year":"1998","unstructured":"Matsuno K, Mita S (1998). SA 4503: a novel sigma-1 receptor agonist. CNS Drug Rev 4: 1\u201324.","journal-title":"CNS Drug Rev"},{"key":"BF1301047_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0166-4328(97)86074-3","volume":"83","author":"K Matsuno","year":"1997","unstructured":"Matsuno K, Senda T, Kobayashi T, Okamoto K, Nakata K, Mita S (1997). SA4503, a novel cognitive enhancer, with sigma-1 receptor agonistic properties. Behav Brain Res 83: 221\u2013224.","journal-title":"Behav Brain Res"},{"key":"BF1301047_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0165-0173(01)00112-6","volume":"37","author":"T Maurice","year":"2001","unstructured":"Maurice T, Urani A, Phan VL, Romieu P (2001). The interaction between neuroactive steroids and the sigma-1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Brain Res Rev 37: 116\u2013132.","journal-title":"Brain Res Brain Res Rev"},{"key":"BF1301047_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/(SICI)1098-2396(199908)33:2<129::AID-SYN3>3.0.CO;2-E","volume":"33","author":"Y Minabe","year":"1999","unstructured":"Minabe Y, Matsuno K, Ashby Jr CR (1999). Acute and chronic administration of the selective sigma1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 33: 129\u2013140.","journal-title":"Synapse"},{"key":"BF1301047_CR28","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0896-6273(03)00757-8","volume":"40","author":"B Moghaddam","year":"2003","unstructured":"Moghaddam B (2003). Bringing order to the glutamate chaos in schizophrenia. Neuron 40: 881\u2013884.","journal-title":"Neuron"},{"key":"BF1301047_CR29","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S0893-133X(01)00368-2","volume":"26","author":"T Morimoto","year":"2002","unstructured":"Morimoto T, Hashimoto K, Yasumatsu H, Tanaka H, Fujimura M, Kuriyama M et al (2002). Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate). Neuropsychopharmacology 26: 456\u2013467.","journal-title":"Neuropsychopharmacology"},{"key":"BF1301047_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0014-2999(96)00254-3","volume":"307","author":"N Narita","year":"1996","unstructured":"Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996). Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307: 117\u2013119.","journal-title":"Eur J Pharmacol"},{"key":"BF1301047_CR31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/sj.npp.1300351","volume":"29","author":"N Okamura","year":"2004","unstructured":"Okamura N, Hashimoto K, Shimizu E, Kumakiri C, Komatsu N, Iyo M (2004). Adenosine A1 receptor agonists block the neuropathological changes in rat retrosplenial cortex after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 29: 544\u2013550.","journal-title":"Neuropsychopharmacology"},{"key":"BF1301047_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1527-3458.1996.tb00299.x","volume":"2","author":"S Okuyama","year":"1996","unstructured":"Okuyama S, Nakazato A (1996). NE-100: a novel sigma receptor antagonist. CNS Drug Rev 2: 226\u2013237.","journal-title":"CNS Drug Rev"},{"key":"BF1301047_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","volume":"52","author":"JW Olney","year":"1995","unstructured":"Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998\u20131007.","journal-title":"Arch Gen Psychiatry"},{"key":"BF1301047_CR34","doi-asserted-by":"crossref","unstructured":"Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M (2006). Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry (in press).","DOI":"10.1016\/j.biopsych.2005.07.031"},{"key":"BF1301047_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0893-133X(97)00200-5","volume":"19","author":"F Sams-Dodd","year":"1998","unstructured":"Sams-Dodd F (1998). Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19: 18\u201325.","journal-title":"Neuropsychopharmacology"},{"key":"BF1301047_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s002130050181","volume":"129","author":"C S\u00e1nchez","year":"1997","unstructured":"S\u00e1nchez C, Meier E (1997). Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berlin) 129: 197\u2013205.","journal-title":"Psychopharmacology (Berlin)"},{"key":"BF1301047_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1527-3458.2001.tb00200.x","volume":"7","author":"H Silver","year":"2001","unstructured":"Silver H (2001). Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7: 283\u2013304.","journal-title":"CNS Drug Rev"},{"key":"BF1301047_CR38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00004850-200311000-00001","volume":"18","author":"H Silver","year":"2003","unstructured":"Silver H (2003). Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int Clin Psychopharmacol 18: 305\u2013313.","journal-title":"Int Clin Psychopharmacol"},{"key":"BF1301047_CR39","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1517\/14656566.5.10.2053","volume":"5","author":"H Silver","year":"2004","unstructured":"Silver H (2004). Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 5: 2053\u20132058.","journal-title":"Expert Opin Pharmacother"},{"key":"BF1301047_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00004850-200015050-00002","volume":"15","author":"H Silver","year":"2000","unstructured":"Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M (2000). Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 15: 257\u2013261.","journal-title":"Int Clin Psychopharmacol"},{"key":"BF1301047_CR41","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2174\/0929867033456783","volume":"10","author":"TP Su","year":"2003","unstructured":"Su TP, Hayashi T (2003). Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 10: 2073\u20132080.","journal-title":"Curr Med Chem"},{"issue":"Suppl 3","key":"BF1301047_CR42","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1055\/s-2004-832679","volume":"37","author":"M Takebayashi","year":"2004","unstructured":"Takebayashi M, Hayashi T, Su TP (2004). A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 37 (Suppl 3): S208\u2013S213.","journal-title":"Pharmacopsychiatry"},{"key":"BF1301047_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/43432","volume":"401","author":"YP Tang","year":"1999","unstructured":"Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M et al (1999). Genetic enhancement of learning and memory in mice. Nature 401: 63\u201369.","journal-title":"Nature"},{"key":"BF1301047_CR44","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0028-3908(01)00122-8","volume":"41","author":"YP Tang","year":"2001","unstructured":"Tang YP, Wang H, Feng R, Kyin M, Tsien JZ (2001). Differential effects of enrichment on learning and memory function in NR2B transgenic mice. Neuropharmacology 41: 779\u2013790.","journal-title":"Neuropharmacology"},{"key":"BF1301047_CR45","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0022-3565(24)29502-1","volume":"298","author":"A Urani","year":"2001","unstructured":"Urani A, Roman FJ, Phan VL, Su TP, Maurice T (2001). The antidepressant-like effect induced by sigma-1 receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 298: 1269\u20131279.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1301047_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00213-002-1150-y","volume":"163","author":"A Urani","year":"2002","unstructured":"Urani A, Romieu P, Portales-Casamar E, Roman FJ, Maurice T (2002). The antidepressant-like effect induced by the sigma-1 receptor agonist igmesine involves modulation of intracellular calcium mobilization. Psychopharmacology (Berlin) 163: 26\u201335.","journal-title":"Psychopharmacology (Berlin)"},{"key":"BF1301047_CR47","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0028-3908(99)00228-2","volume":"39","author":"LB Zou","year":"2000","unstructured":"Zou LB, Yamada K, Sasa M, Nakata Y, Nabeshima T (2000). Effects of sigma-1 receptor agonist SA4503 and neuroactive steroids on performance in a radial arm maze task in rats. Neuropharmacology 39: 1617\u20131627.","journal-title":"Neuropharmacology"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/1301047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1301047","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/1301047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T16:08:36Z","timestamp":1736266116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1301047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,22]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["BF1301047"],"URL":"https:\/\/doi.org\/10.1038\/sj.npp.1301047","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,22]]}}}